Last updated today
Editas Medicine is a discovery-phase pharmaceutical company based in Cambridge, Massachusetts which aims to develop therapies based on CRISPR–Cas9 gene editing technology. It was founded in 2013 with funding from Third Rock Ventures, Polaris Partners and Flagship Ventures and licensed CRISPR patents from the Broad Institute's Feng Zhang, patents from Harvard's David Liu and George Church and patents from Partners Healthcare-MGH's J. Keith Joung.
Last updated today
Coming soon.
No recent security news.
More security reports
Cybersecurity & Risk Management Library
The ultimate guide to attack surface and third-party risk management – actionable advice for security teams, managers, and executives.
Breaches
Security research and global news about data breaches.
Explore resources
Third-party risk management
Articles, news, and research on third-party risk management.
Explore resources
Attack Surface Management
Articles, news, and research on attack surface management.
Explore resources
Cybersecurity
Articles, news, and research on cybersecurity.
Explore resources
Leader in Third Party & Supplier Risk Management Software
See how UpGuard shapes up against other platforms in the market.
"This is some text inside of a div block."
Free instant security score
How secure is your organization?
Request a free cybersecurity report to discover key risks on your website, email, network, and brand.
- Instant insights you can act on immediately
- Hundreds of risk factors including email security, SSL, DNS health, open ports and common vulnerabilities
Want a full vendor security report for this company?
Start your free trial and unlock real-time insights to identify and assess vendor risks.